Literature DB >> 6542069

Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.

H Sato, Y Sato.   

Abstract

The correlation of titers of specific serum immunoglobulin G antibodies against two antigens, pertussis toxin (PT), and filamentous hemagglutinin (FHA), which are the main components of pertussis vaccine in Japan, with mouse protectivity was examined by both intracerebral and aerosol challenge systems with virulent Bordetella pertussis cells. Titer of the antibodies was calculated from the enzyme-linked immunosorbent assay (ELISA) unit given arbitrarily to reference antibodies. PT antibody titer which protected 50% of mice was indistinguishable in both active immunization followed by intracerebral challenge and passive immunization followed by aerosol challenge. The 50% effective dose was 23 ELISA U/ml in the former mice and 24 ELISA U/mouse in the latter. In the intracerebral challenge system, FHA did not elicit a protective response but was very helpful for PT as an immunizing antigen. When anti-FHA immunoglobulin G coexisted with anti-PT immunoglobulin G in mice, the 50% effective dose of PT antibody was 4.4 or 10 ELISA U/mouse in intracerebral or aerosol challenge systems, respectively. In this active immunization system, pertussis toxoid of 1 micrograms or 0.1 microgram/mouse produced PT antibody of ca. 20 or 5 ELISA U/ml, respectively. It was concluded that pertussis toxoid or its antibody was much more potent than Formalin-treated FHA or its antibody; Formalin-treated FHA or its antibody was helpful when it was administered with pertussis toxoid toxoid or its antibody, however.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542069      PMCID: PMC261548          DOI: 10.1128/iai.46.2.415-421.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

Review 1.  Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.

Authors:  M Pittman
Journal:  Rev Infect Dis       Date:  1979 May-Jun

2.  Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis.

Authors:  H Arai; Y Sato
Journal:  Biochim Biophys Acta       Date:  1976-10-22

3.  Leucocytosis-promoting factor of Bordetella pertussis. I. Purification and characterization.

Authors:  Y Sato; H Arai
Journal:  Infect Immun       Date:  1972-12       Impact factor: 3.441

4.  Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

5.  Separation and purification of the hemagglutinins from Bordetella pertussis.

Authors:  Y Sato; J L Cowell; H Sato; D G Burstyn; C R Manclark
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

6.  Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice.

Authors:  A Robinson; L I Irons
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

7.  Leukocytosis-promoting factor of Bordetella pertussis. II. Biological properties.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1973-06       Impact factor: 3.441

8.  Aerosol infection of mice with Bordetella pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

9.  Leukocytosis-promoting factor of Bordetella pertussis. 3. Its identity with protective antigen.

Authors:  Y Sato; H Arai; K Suzuki
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

10.  Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

Authors:  J J Munoz; H Arai; R L Cole
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

View more
  50 in total

1.  Pertussis: the disease and the vaccine.

Authors:  R Gold
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

2.  Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.

Authors:  W N Burnette; J L Arciniega; V L Mar; D L Burns
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

3.  Identification of linear B-cell determinants of pertussis toxin associated with the receptor recognition site of the S3 subunit.

Authors:  M A Schmidt; B Raupach; M Szulczynski; J Marzillier
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.

Authors:  H Sato; Y Sato; I Ohishi
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

5.  Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose.

Authors:  G D Armstrong; M S Peppler
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.

Authors:  M S Goodwin; A A Weiss
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

7.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 8.  Pertussis: the disease and new diagnostic methods.

Authors:  R L Friedman
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

9.  Pertussis toxin is required for pertussis vaccine encephalopathy.

Authors:  L Steinman; A Weiss; N Adelman; M Lim; R Zuniga; J Oehlert; E Hewlett; S Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

Review 10.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.